Cooperative Agreement U54CA302435
Award Date 8/22/25
Completion Date 7/31/30
Dollars Obligated $2.6M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Texas, USA
Similar Awards
- This federal Project Grant award, valued at $192,240.00, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The grant supports research to determine the role of mosaic chromosomal alterations (MCAs) in the risk and prognosis of lymphoid malignancies, which are common forms of cancer. The research, conducted by the University of Texas MD Anderson Cancer Center, aims to characterize the association between MCAs and the risk of specific...
- The National Cancer Institute (NCI) awarded a $5,041,790 Cooperative Agreement under the Cancer Centers Support Grants (CFDA 93.397) program to the University of California, San Francisco (UCSF) to improve cancer health disparities. The 5-year project, starting on August 1, 2025, will investigate the interplay of tumor genomic and immune characteristics with individual risk factors and social and structural drivers of health across three diverse cancers: meningioma, prostate cancer, and breast...
- The Baylor College of Medicine has been awarded a $2,494,110 Cooperative Agreement from the National Cancer Institute (CFDA 93.397 Cancer Centers Support Grants) to conduct research aimed at reducing ethnic disparities in outcomes for children and adolescents with acute lymphoblastic leukemia (ALL). The 5-year project, titled "Reducing Ethnic Disparities in Acute Leukemia (REDIAL)", will investigate multifactorial causes of poorer ALL outcomes among Latino patients, including studies...
- The National Cancer Institute (NCI) awarded a $244,228 Project Grant to the University of Texas MD Anderson Cancer Center under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award, effective March 11, 2025 through February 28, 2027, will fund research to develop a functional proteomics approach to accurately map patient tumor samples with preclinical cancer models, with the goal of increasing treatment response rates and minimizing drug resistance in lung cancer. The...
- The National Cancer Institute (NCI) awarded a $825,966 Project Grant to the University of Texas MD Anderson Cancer Center under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The grant, which has an award date of September 4, 2025 and an ultimate completion date of August 31, 2030, will fund a randomized controlled trial to test the effects of a multilevel, culturally adapted storytelling intervention. The intervention aims to address stigma at both the patient and...
- The University of North Carolina at Chapel Hill (UNC-CH) received a $2,255,110 Cooperative Agreement award on September 4, 2025 from the National Cancer Institute (NCI) under the Cancer Centers Support Grants (CFDA 93.397) program. The award will support a Cancer Health Disparities SPORE (Specialized Programs of Research Excellence) in Endometrial Cancer, a multi-disciplinary translational research initiative aimed at studying biological and social factors driving disparities in endometrial...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $525,013 to The University of Texas MD Anderson Cancer Center to validate the predictive performance of two blood-based biomarker panels (4-protein and 4-metabolite) for assessing the 1-year risk of lung cancer among individuals with no smoking history. The project aims to develop a composite panel that combines these biomarkers with clinical risk characteristics...
- This $728,043.00 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program supports research by the University of Texas M.D. Anderson Cancer Center (M.D. Anderson) to delineate the tumor ecology and genomic progression of lobular breast cancers. The 3-year project, running from February 1, 2025 to January 31, 2028, aims to advance the understanding of this specific type of breast cancer through innovative scientific...
- The U.S. Defense Health Agency awarded a $19,100,256 Cooperative Agreement to The University of Texas M.D. Anderson Cancer Center for the "CONVERGENT SCIENCE CANCER CONSORTIUM FOR IMMUNE CELL ENGINEERING" project under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award period runs from August 1, 2025 to July 31, 2029. The funding supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and...
- The University of Florida was awarded a $589,591 Project Grant from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot federal grant program (CFDA 93.353). The grant, awarded on February 1, 2025, supports a 5-year research project to determine how social factors influence survival outcomes for Black and Hispanic patients with Hodgkin lymphoma. The research aims to identify barriers and predictors of variation in treatment and survivorship care...